Document text
Principal Investigator: Margaret Juliana McElrath
Organization: SEATTLE CHILDREN'S HOSPITAL
Fiscal Year: 2024
Award: $2,100,000
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT (Overall)
Malaria, HIV/AIDS, and Covid are three of the most devastating infectious diseases, impacting millions of people
world-wide. Effective vaccines against the pathogens that cause these diseases (HIV, SARS-CoV-2 and
Plasmodium falciparum) have proven elusive and/or affected by pathogen variation and thus traditional vaccine
approaches are unlikely to succeed in eradicating these diseases. In addition to our limited understanding of the
desired immune responses to confer protection against the pathogens and our limited ability to elicit such
responses, vaccine efficacy is also confounded by the diversity of pathogens, human populations, environmental
exposures, and health status. The projects described herein are designed to support the identification of immune
profiles that correlate with vaccine efficacy and are of potential relevance to protection against HIV-1, SARS
CoV-2 and P. falciparum infection. Beyond the importance of combatting these diseases, the strategies for
profiling immunity in response to infection and vaccination hold promise for garnering fundamental insights into
the complexity of the human immune system. Such insights have the potential to impact strategies for vaccine
development and for producing new therapies for many diseases.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><AIDS/HIV><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adjuvant><Affect><COVID-19 infection><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 virus><Characteristics><CoV-2><CoV2><Communicable Diseases><Communities><Data Analyses><Data Analysis><Development><Disease><Disorder><Environmental Exposure><Falciparum Malaria><Foundations><Future><Goals><HIV><HIV-1><HIV-I><HIV/AIDS><HIV1><Health Status><Human><Human Characteristics><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human Nature><Human immunodeficiency virus 1><Immune><Immune response><Immune system><Immunes><Immunity><Immunization><Immunological response><Immunology><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Institution><LAV-HTLV-III><Level of Health><Lymphadenopathy-Associated Virus><Malaria><Modern Man><Molecular Fingerprinting><Molecular Profiling><Outcome><P falciparum><P. falciparum><P.falciparum><Paludism><Persons><Plasmodium Infections><Plasmodium falciparum><Plasmodium falciparum Malaria><Population><Predisposition><Preventative strategy><Prevention><Prevention strategy><Preventive strategy><Process><Research><Resolution><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Susceptibility><System><Systems Biology><Technical Expertise><Technology><Therapeutic><Vaccination><Vaccines><Variant><Variation><Virus-HIV><Wuhan coronavirus><coronavirus disease 2019 infection><coronavirus disease 2019 virus><coronavirus disease-19 virus><data interpretation><data standardization><data standards><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><hCoV19><health level><host response><human disease><immune response to vaccination><immune response to vaccines><immune system response><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><malaria infection><malaria-infected><malarial infection><molecular profile><molecular signature><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathogen><resolutions><response><technical skills><treatment strategy><vaccine associated immune response><vaccine development><vaccine efficacy><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine strategy>